Bruni Cosimo, Buch Maya H, Furst Daniel E, De Luca Giacomo, Djokovic Aleksandra, Dumitru Raluca B, Giollo Alessandro, Polovina Marija, Steelandt Alexia, Bratis Kostantinos, Suliman Yossra Atef, Milinkovic Ivan, Baritussio Anna, Hasan Ghadeer, Xintarakou Anastasia, Isomura Yohei, Markousis-Mavrogenis George, Tofani Lorenzo, Mavrogeni Sophie, Gargani Luna, Caforio Alida Lp, Tschöpe Carsten, Ristic Arsen, Klingel Karin, Plein Sven, Behr Elijah R, Allanore Yannick, Kuwana Masataka, Denton Christopher P, Khanna Dinesh, Krieg Thomas, Marcolongo Renzo, Galetti Ilaria, Zanatta Elisabetta, Tona Francesco, Seferovic Petar, Matucci-Cerinic Marco
Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy.
Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
J Scleroderma Relat Disord. 2022 Feb;7(1):24-32. doi: 10.1177/23971983211053246. Epub 2021 Oct 26.
Primary heart involvement in systemic sclerosis may cause morpho-functional and electrical cardiac abnormalities and is a common cause of death. The absence of a clear definition of primary heart involvement in systemic sclerosis limits our understanding and ability to focus on clinical research. We aimed to create an expert consensus definition for primary heart involvement in systemic sclerosis.
A systematic literature review of cardiac involvement and manifestations in systemic sclerosis was conducted to inform an international and multi-disciplinary task force. In addition, the nominal group technique was used to derive a definition that was then subject to voting. A total of 16 clinical cases were evaluated to test face validity, feasibility, reliability and criterion validity of the newly created definition.
In total, 171 publications met eligibility criteria. Using the nominal group technique, experts added their opinion, provided statements to consider and ranked them to create the consensus definition, which received 100% agreement on face validity. A median 60(5-300) seconds was taken for the feasibility on a single case. Inter-rater agreement was moderate (mKappa (95% CI) = 0.56 (0.46-1.00) for the first round and 0.55 (0.44-1.00) for the second round) and intra-rater agreement was good (mKappa (95% CI) = 0.77 (0.47-1.00)). Criterion validity showed a 78 (73-84)% correctness versus gold standard.
A preliminary primary heart involvement in systemic sclerosis consensus-based definition was created and partially validated, for use in future clinical research.
系统性硬化症累及心脏可导致心脏形态功能和电活动异常,是常见的死亡原因。目前缺乏系统性硬化症心脏受累的明确定义,限制了我们对其的理解以及专注于临床研究的能力。我们旨在制定系统性硬化症心脏受累的专家共识定义。
对系统性硬化症心脏受累及表现进行系统的文献综述,为一个国际多学科特别工作组提供信息。此外,采用名义群体技术得出一个定义,然后进行投票。共评估了16例临床病例,以检验新制定定义的表面效度、可行性、可靠性和标准效度。
共有171篇出版物符合纳入标准。通过名义群体技术,专家们发表意见、提供需考虑的陈述并进行排序,以形成共识定义,该定义在表面效度上获得了100%的认可。单个病例的可行性评估中位数为60(5 - 300)秒。评分者间一致性为中等(第一轮mKappa(95%CI)= 0.56(0.46 - 1.00),第二轮为0.55(0.44 - 1.00)),评分者内一致性良好(mKappa(95%CI)= 0.77(0.47 - 1.00))。标准效度显示与金标准相比正确度为78(73 - 84)%。
制定了一个基于共识的系统性硬化症心脏受累初步定义,并进行了部分验证,供未来临床研究使用。